Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.

Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, McMahon L, Cony-Makhoul P, Byrne J, Smith G, Koschmieder S, BrÜmmendorf TH, Schafhausen P, Gallipoli P, Thomson F, Cong W, Clark RE, Milojkovic D, Helgason GV, Foroni L, Nicolini FE, Holyoake TL, Copland M.

Leukemia. 2020 Jan 10. doi: 10.1038/s41375-019-0700-9. [Epub ahead of print]

PMID:
31925317
2.

Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the Rhône-Alpes Region.

Dony A, Belhabri A, Bertrand Y, Sebban C, Cony-Makhoul P, Sobh M, Rogasik M, Salles G, Anglaret B, Freycon C, Corm S, Faurie P, Cornillon J, Michallet AS, Chassagne-Clément C, Berger F, Ray-Coquard IL.

J Adolesc Young Adult Oncol. 2019 Dec;8(6):684-696. doi: 10.1089/jayao.2019.0016. Epub 2019 Aug 14.

PMID:
31411521
3.

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.

Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V, Lenain P, Rousselot P, Rea D, Guerci-Bresler A, Legros L, Liu J, Gardembas M, Ianotto JC, Turlure P, Johnson-Ansah H, Martiniuc J, Jardel H, Joly B, Zunic P, Henni T, Villemagne B, Berger MG, Cayssials E, Guilhot F, Larosa F, Guilhot J, Etienne G, Mahon FX.

Clin Cancer Res. 2019 Nov 15;25(22):6606-6613. doi: 10.1158/1078-0432.CCR-18-3373. Epub 2019 Jul 10.

PMID:
31292142
4.

Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.

Berger MG, Pereira B, Rousselot P, Cony-Makhoul P, Gardembas M, Legros L, Escoffre-Barbe M, Nicolini FE, Saugues S, Lambert C, Réa D, Guerci-Bresler A, Giraudier S, Guilhot J, Saussele S, Mahon FX; (France Intergroupe des Leucémies Myéloïdes Chroniques).

Br J Haematol. 2019 Nov;187(3):337-346. doi: 10.1111/bjh.16083. Epub 2019 Jul 4.

PMID:
31271217
5.

Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study.

Foulon S, Cony-Makhoul P, Guerci-Bresler A, Delord M, Solary E, Monnereau A, Bonastre J, Tubert-Bitter P.

Cancer Med. 2019 Jun;8(6):3296-3304. doi: 10.1002/cam4.2200. Epub 2019 Apr 30.

6.

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Pertesi M, Vallée M, Wei X, Revuelta MV, Galia P, Demangel D, Oliver J, Foll M, Chen S, Perrial E, Garderet L, Corre J, Leleu X, Boyle EM, Decaux O, Rodon P, Kolb B, Slama B, Mineur P, Voog E, Le Bris C, Fontan J, Maigre M, Beaumont M, Azais I, Sobol H, Vignon M, Royer B, Perrot A, Fuzibet JG, Dorvaux V, Anglaret B, Cony-Makhoul P, Berthou C, Desquesnes F, Pegourie B, Leyvraz S, Mosser L, Frenkiel N, Augeul-Meunier K, Leduc I, Leyronnas C, Voillat L, Casassus P, Mathiot C, Cheron N, Paubelle E, Moreau P, Bignon YJ, Joly B, Bourquard P, Caillot D, Naman H, Rigaudeau S, Marit G, Macro M, Lambrecht I, Cliquennois M, Vincent L, Helias P, Avet-Loiseau H, Moreno V, Reis RM, Varkonyi J, Kruszewski M, Vangsted AJ, Jurczyszyn A, Zaucha JM, Sainz J, Krawczyk-Kulis M, Wątek M, Pelosini M, Iskierka-Jażdżewska E, Grząśko N, Martinez-Lopez J, Jerez A, Campa D, Buda G, Lesueur F, Dudziński M, García-Sanz R, Nagler A, Rymko M, Jamroziak K, Butrym A, Canzian F, Obazee O, Nilsson B, Klein RJ, Lipkin SM, McKay JD, Dumontet C.

Leukemia. 2019 Sep;33(9):2324-2330. doi: 10.1038/s41375-019-0452-6. Epub 2019 Apr 9. No abstract available.

7.

Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.

Bidet A, Dulucq S, Smol T, Marceau-Renaut A, Morisset S, Coiteux V, Noël-Walter MP, Nicolini FE, Tigaud I, Luquet I, Struski S, Gaillard B, Penther D, Tondeur S, Nadal N, Hermet E, Véronèse L, Réa D, Gervais C, Theisen O, Terré C, Cony-Makhoul P, Lefebvre C, Gaillard JB, Radford I, Vervaeke AL, Barin C, Chapiro E, Nguyen-Khac F, Etienne G, Preudhomme C, Mahon FX, Roche-Lestienne C; Groupe Francophone de Cytogénétique Hématologique (GFCH) and the French Intergroup of Chronic Myeloid Leukemia (Fi-LMC).

Haematologica. 2019 Jun;104(6):1150-1155. doi: 10.3324/haematol.2018.208801. Epub 2018 Dec 20.

8.

A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM).

Ades L, Guerci-Bresler A, Cony-Makhoul P, Legros L, Sebert M, Braun T, Delaunay J, Desseaux K, Chevret S, Fenaux P.

Haematologica. 2019 Apr;104(4):e131-e133. doi: 10.3324/haematol.2018.203885. Epub 2018 Oct 31. No abstract available.

9.

Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib.

Nicolini FE, Alcazer V, Cony-Makhoul P, Heiblig M, Morisset S, Fossard G, Bidet A, Schmitt A, Sobh M, Hayette S, Mahon FX, Dulucq S, Etienne G.

Exp Hematol. 2018 Aug;64:97-105.e4. doi: 10.1016/j.exphem.2018.05.003. Epub 2018 May 23.

PMID:
29800673
10.

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

Rea D, Ame S, Berger M, Cayuela JM, Charbonnier A, Coiteux V, Cony-Makhoul P, Dubruille V, Dulucq S, Etienne G, Legros L, Nicolini F, Roche-Lestienne C, Escoffre-Barbe M, Gardembas M, Guerci-Bresler A, Johnson-Ansah H, Rigal-Huguet F, Rousselot P, Mahon FX; French Chronic Myeloid Leukemia Study Group.

Cancer. 2018 Jul 15;124(14):2956-2963. doi: 10.1002/cncr.31411. Epub 2018 May 3.

11.

DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+ CD15- cells in early chronic-phase chronic myeloid leukemia.

Maupetit-Mehouas S, Court F, Bourgne C, Guerci-Bresler A, Cony-Makhoul P, Johnson H, Etienne G, Rousselot P, Guyotat D, Janel A, Hermet E, Saugues S, Berger J, Arnaud P, Berger MG.

Mol Oncol. 2018 Jun;12(6):814-829. doi: 10.1002/1878-0261.12191. Epub 2018 Apr 27.

12.

Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase.

Cony-Makhoul P, Gardembas M, Coiteux V, Carpentier N, Pommier C, Violet I, Quittet P, Berger MG; TARGET-RMC Investigators.

Br J Haematol. 2018 Feb;180(3):356-364. doi: 10.1111/bjh.15042. Epub 2017 Dec 19.

PMID:
29265184
13.

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.

Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, de Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Benbrahim O, Ugo V, Lippert E, Kiladjian JJ.

Haematologica. 2018 Mar;103(3):438-446. doi: 10.3324/haematol.2017.181297. Epub 2017 Dec 7.

14.

Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.

Ruggiu M, Oberkampf F, Ghez D, Cony-Makhoul P, Beckeriche F, Cano I, Taksin AL, Benbrahim O, Ghez S, Farhat H, Rigaudeau S, de Gunzburg N, Lara D, Terre C, Raggueneau V, Garcia I, Spentchian M, De Botton S, Rousselot P.

Leuk Lymphoma. 2018 Jul;59(7):1659-1665. doi: 10.1080/10428194.2017.1397666. Epub 2017 Nov 28.

PMID:
29179634
15.

First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.

Goldberg SL, Cortes JE, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Michallet M, Paquette RL, Simonsson B, Zyczynski T, Foreman A, Abruzzese E, Andorsky D, Beeker A, Cony-Makhoul P, Hansen R, Lomaia E, Olavarria E, Mauro MJ.

Am J Hematol. 2017 Nov;92(11):1214-1223. doi: 10.1002/ajh.24887. Epub 2017 Sep 25.

16.

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P.

J Clin Oncol. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28.

PMID:
28350519
17.

Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.

Rousselot P, Prost S, Guilhot J, Roy L, Etienne G, Legros L, Charbonnier A, Coiteux V, Cony-Makhoul P, Huguet F, Cayssials E, Cayuela JM, Relouzat F, Delord M, Bruzzoni-Giovanelli H, Morisset L, Mahon FX, Guilhot F, Leboulch P; French CML Group.

Cancer. 2017 May 15;123(10):1791-1799. doi: 10.1002/cncr.30490. Epub 2016 Dec 27.

18.

Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies.

Prebet T, Delaunay J, Wattel E, Braun T, Cony-Makhoul P, Dimicoli S, Wickenhauser S, Lejeune J, Chevret S, Chermat F, Fenaux P, Vey N; Groupe Francophone des Myélodysplasies.

Br J Haematol. 2018 Mar;180(5):735-737. doi: 10.1111/bjh.14427. Epub 2016 Dec 15. No abstract available.

PMID:
27977052
19.

CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment.

Nicolini FE, Alcazer V, Huguet F, Cony-Makhoul P, Heiblig M, Fort MP, Morisset S, Guerci-Bresler A, Soula V, Sobh M, d'Estaing SG, Daudin M, Etienne G.

Leuk Res. 2016 Sep;48:80-3. doi: 10.1016/j.leukres.2016.07.008. Epub 2016 Jul 22. No abstract available.

PMID:
27501271
20.

Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study.

Etienne G, Huguet F, Guerci-Bresler A, Nicolini FE, Maloisel F, Coiteux V, Dauriac C, Carpentier N, Bourdeix I, Tulliez M, Cony-Makhoul P.

Br J Haematol. 2016 Jul;174(1):71-80. doi: 10.1111/bjh.14022. Epub 2016 Apr 7.

PMID:
27060881
21.

[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].

Rea D, Ame S, Charbonnier A, Coiteux V, Cony-Makhoul P, Escoffre-Barbe M, Etienne G, Gardembas M, Guerci-Bresler A, Legros L, Nicolini F, Tulliez M, Hermet E, Huguet F, Johnson-Ansah H, Lapusan S, Quittet P, Rousselot P, Mahon FX, Messas E.

Bull Cancer. 2016 Feb;103(2):180-9. doi: 10.1016/j.bulcan.2015.11.008. Epub 2016 Jan 11. French.

PMID:
26790711
22.

Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.

Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, Giraudier S, Coiteux V, Guerci-Bresler A, Lenain P, Cony-Makhoul P, Gardembas M, Hermet E, Rousselot P, Amé S, Gagnieu MC, Pivot C, Hayette S, Maguer-Satta V, Etienne M, Dulucq S, Rea D, Mahon FX.

Lancet Haematol. 2015 Jan;2(1):e37-46. doi: 10.1016/S2352-3026(14)00027-1. Epub 2015 Jan 7.

PMID:
26687426
23.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F.

Leukemia. 2016 Apr;30(4):897-905. doi: 10.1038/leu.2015.296. Epub 2015 Oct 26.

24.

Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis.

Herbaux C, Duployez N, Badens C, Poret N, Gardin C, Decamp M, Eclache V, Daliphard S, Murati A, Cony-Makhoul P, Cheze S, Beve B, Lacoste C, Prebet T, Hunault-Berger M, Maloisel F, Renneville A, Figeac M, Stamatoullas-Bastard A, Bastard C, Fenaux P, Preudhomme C, Rose C; GFM (Groupe Francophone des Myelodysplasies).

Am J Hematol. 2015 Aug;90(8):737-8. doi: 10.1002/ajh.24073.

25.

Early-onset hypogammaglobulinemia: A survey of 44 patients.

Brignier AC, Mahlaoui N, Reimann C, Picard C, Kracker S, de Vergnes N, Rieux-Laucat F, Frange P, Suarez F, Neven B, Masseau A, Aladjidi N, Donadieu J, Corby A, Bienvenu B, Cony-Makhoul P, Fischer A, Cavazzana M, Durandy A.

J Allergy Clin Immunol. 2015 Oct;136(4):1097-9.e2. doi: 10.1016/j.jaci.2015.03.038. Epub 2015 May 8. No abstract available.

PMID:
25959671
26.

Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia.

Mondet J, Park JH, Menard A, Marzac C, Carillo S, Pourcelot E, Girodon F, Cabagnols X, Lodé L, Socoro N, Chauvet M, Bulabois CE, Cony-Makhoul P, Corm S, Cahn JY, Mossuz P.

Haematologica. 2015 May;100(5):e176-8. doi: 10.3324/haematol.2014.118927. Epub 2015 Feb 6. No abstract available.

27.

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.

Rodon P, Hulin C, Pegourie B, Tiab M, Anglaret B, Benboubker L, Jardel H, Decaux O, Kolb B, Roussel M, Garderet L, Leleu X, Fitoussi O, Chaleteix C, Casassus P, Lenain P, Royer B, Banos A, Benramdane R, Cony-Makhoul P, Dib M, Fontan J, Stoppa AM, Traullé C, Vilque JP, Pétillon MO, Mathiot C, Dejoie T, Avet-Loiseau H, Moreau P.

Haematologica. 2015 Feb;100(2):e56-9. doi: 10.3324/haematol.2014.110890. Epub 2014 Nov 14. No abstract available.

28.

Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.

Huet S, Cony-Makhoul P, Heiblig M, Tigaud I, Gazzo S, Belhabri A, Souche D, Michallet M, Magaud JP, Hayette S, Nicolini F.

PLoS One. 2014 Sep 9;9(9):e106250. doi: 10.1371/journal.pone.0106250. eCollection 2014.

29.

Reply to J. Richter et al.

Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX.

J Clin Oncol. 2014 Sep 1;32(25):2823-5. doi: 10.1200/JCO.2014.56.3858. Epub 2014 Jul 28. No abstract available.

PMID:
25071119
30.

Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia.

Cornet E, Tomowiak C, Tanguy-Schmidt A, Lepretre S, Dupuis J, Feugier P, Devidas A, Mariette C, Leblond V, Thiéblemont C, Validire-Charpy P, Sutton L, Gyan E, Eisenmann JC, Cony-Makhoul P, Ysebaert L, Troussard X; Société Française d'Hématologie.

Br J Haematol. 2014 Aug;166(3):390-400. doi: 10.1111/bjh.12908. Epub 2014 Apr 18.

PMID:
24749839
31.

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX.

J Clin Oncol. 2014 Feb 10;32(5):424-30. doi: 10.1200/JCO.2012.48.5797. Epub 2013 Dec 9.

PMID:
24323036
32.

The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases.

Legrand F, Renneville A, MacIntyre E, Mastrilli S, Ackermann F, Cayuela JM, Rousselot P, Schmidt-Tanguy A, Fain O, Michel M, de Jaureguiberry JP, Hatron PY, Cony-Makhoul P, Lefranc D, Sène D, Cottin V, Hamidou M, Lidove O, Baruchel A, Dubucquoi S, Bletry O, Preudhomme C, Capron M, Prin L, Kahn JE; French Eosinophil Network.

Medicine (Baltimore). 2013 Sep;92(5):e1-e9. doi: 10.1097/MD.0b013e3182a71eba.

33.

Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.

Ianotto JC, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, De Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Schoenwald M, Andreoli A, Abgrall JF, Kiladjian JJ.

Br J Haematol. 2013 Sep;162(6):783-91. doi: 10.1111/bjh.12459. Epub 2013 Jul 13.

PMID:
23848933
34.

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.

Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T.

J Clin Oncol. 2013 Jan 1;31(1):104-10. doi: 10.1200/JCO.2012.43.7285. Epub 2012 Oct 29.

PMID:
23109692
35.

Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study.

Rousselot P, Cony-Makhoul P, Nicolini F, Mahon FX, Berthou C, Réa D, Reiffers J, Bornand A, Saint-Jean O, Guilhot J, Guilhot F; French Intergroup For Chronic Myelogenous Leukemia (Fi-LMC).

Am J Hematol. 2013 Jan;88(1):1-4. doi: 10.1002/ajh.23330. Epub 2012 Sep 17.

36.

First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia.

Rea D, Etienne G, Nicolini F, Cony-Makhoul P, Johnson-Ansah H, Legros L, Huguet F, Tulliez M, Gardembas M, Bouabdallah K, Rousselot P, Cayuela JM, Guilhot F, Mahon FX.

Leukemia. 2012 Oct;26(10):2254-9. doi: 10.1038/leu.2012.92. Epub 2012 Mar 30.

PMID:
22460758
37.

Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience.

Avet-Loiseau H, Roussel M, Campion L, Leleu X, Marit G, Jardel H, Dib M, Decaux O, Lamy T, Tiab M, Cony-Makhoul P, Banos A, Lepeu G, Lifermann F, Macro M, Kolb B, Hulin C, Caillot D, Traulle C, Mathiot C, Royer B.

Leukemia. 2012 Jan;26(1):158-9. doi: 10.1038/leu.2011.176. Epub 2011 Jul 29. No abstract available.

PMID:
21799511
38.

[Practice guidelines of the use of bisphosphonates in solid tumours with bone metastases and in multiple myeloma].

Brantus JF, Roemer-Becuwe C, Cony-Makhoul P, Salino S, Fontana A, Debourdeau P, Thomas T, Guastalla JP, Ghesquieres H, Sebban C, Pavic M, Collet P, Larbre JP, Martinon S, Brocard F, Bodard AG, Blanc G, Balestrière V, Favier B, Farsi F, Krakowski I, Biron P; Réseau régional Rhône-Alpin (GIP ONCORA).

Rev Med Interne. 2011 Aug;32(8):494-505. doi: 10.1016/j.revmed.2010.11.007. Epub 2011 Mar 3. French.

PMID:
21376431
39.

The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).

Deau B, Nicolini FE, Guilhot J, Huguet F, Guerci A, Legros L, Pautas C, Berthou C, Guyotat D, Cony-Makhoul P, Gardembas M, Michallet M, Hayette S, Cayuela JM, Weiss IR, Réa D, Castaigne S, Mahon FX, Guilhot F, Rousselot P.

Leuk Res. 2011 Jun;35(6):777-82. doi: 10.1016/j.leukres.2010.11.004. Epub 2010 Dec 10.

PMID:
21145590
40.

Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.

Hayette S, Chabane K, Michallet M, Michallat E, Cony-Makhoul P, Salesse S, Maguer-Satta V, Magaud JP, Nicolini FE.

Leuk Res. 2011 Jan;35(1):38-43. doi: 10.1016/j.leukres.2010.06.030. Epub 2010 Jul 29.

PMID:
20673586
41.

Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy.

Rea D, Etienne G, Corm S, Cony-Makhoul P, Gardembas M, Legros L, Dubruille V, Hayette S, Mahon FX, Cayuela JM, Nicolini FE.

Leukemia. 2009 Jun;23(6):1193-6. doi: 10.1038/leu.2009.32. Epub 2009 Feb 26. No abstract available.

PMID:
19242496
42.

[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].

Cony-Makhoul P, Bergeron A, Corm S, Dubruille V, Rea D, Rigal-Huguet F, Nicolini FE.

Bull Cancer. 2008 Sep;95(9):805-11. doi: 10.1684/bdc.2008.0703. French.

43.

Histological features of acute hepatitis after imatinib mesylate treatment.

James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX.

Leukemia. 2003 May;17(5):978-9. No abstract available.

PMID:
12750713
44.

Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.

Barthe C, Gharbi MJ, Lagarde V, Chollet C, Cony-Makhoul P, Reiffers J, Goldman JM, Melo JV, Mahon FX.

Br J Haematol. 2002 Oct;119(1):109-11.

PMID:
12358910
45.

Imatinib mesylate and gray hair.

Etienne G, Cony-Makhoul P, Mahon FX.

N Engl J Med. 2002 Aug 8;347(6):446. No abstract available.

PMID:
12167692
46.

Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571.

Tabrizi R, Mahon FX, Cony Makhoul P, Lagarde V, Lacombe F, Berthaud P, Melo JV, Reiffers J, Belloc F.

Leukemia. 2002 Jun;16(6):1154-9.

47.

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E; International STI571 CML Study Group.

N Engl J Med. 2002 Feb 28;346(9):645-52. Erratum in: N Engl J Med 2002 Jun 13;346(24):1923.

48.

Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa.

Mahon FX, Delbrel X, Cony-Makhoul P, Fabères C, Boiron JM, Barthe C, Bilhou-Nabéra C, Pigneux A, Marit G, Reiffers J.

J Clin Oncol. 2002 Jan 1;20(1):214-20.

PMID:
11773172
49.

Roots of clinical resistance to STI-571 cancer therapy.

Barthe C, Cony-Makhoul P, Melo JV, Mahon JR.

Science. 2001 Sep 21;293(5538):2163. No abstract available.

50.

A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients.

Fitoussi O, Perreau V, Boiron JM, Bouzigon E, Cony-Makhoul P, Pigneux A, Agape P, Nicolini F, Dazey B, Reiffers J, Salmi R, Marit G.

Bone Marrow Transplant. 2001 Apr;27(8):837-42.

Supplemental Content

Loading ...
Support Center